Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2026

Conditions
Leukemia, Lymphoid
Interventions
DRUG

blinatumomab

The dose of one course was as follows: day 1-2: 8ug/day, continuous intravenous drip for 24 hours, day 3-7: 16ug/day, continuous intravenous drip for 24 hours. Dexamethasone 20mg was administered 1 hour before administration on days 1 and 3 to prevent adverse events.

Trial Locations (1)

610044

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
lead

Sichuan University

OTHER